The article below may contain offensive and/or incorrect content.
The FDA has approved a new drug named Ozanimod for the treatment of multiple sclerosis. Ozanimod binds to receptors in lymphocytes' surfaces, preventing them from reaching the brain. As the number of active lymphocytes decreases, the attack on the immune system diminishes.